-
1
-
-
0037567428
-
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
-
Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348:2386-2395.
-
(2003)
N Engl J Med
, vol.348
, pp. 2386-2395
-
-
Diehl, V.1
Franklin, J.2
Pfreundschuh, M.3
-
2
-
-
23044452477
-
Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group
-
Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23:4634-4642.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4634-4642
-
-
Meyer, R.M.1
Gospodarowicz, M.K.2
Connors, J.M.3
-
3
-
-
0032548107
-
A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease
-
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506-1514.
-
(1998)
N Engl J Med
, vol.339
, pp. 1506-1514
-
-
Hasenclever, D.1
Diehl, V.2
-
4
-
-
0035871347
-
Comparison of prognostic models in patients with advanced Hodgkin's disease
-
Gobbi PG, Zinzani PL, Broglia C, et al. Comparison of prognostic models in patients with advanced Hodgkin's disease. Cancer 2001; 91:1467-1478.
-
(2001)
Cancer
, vol.91
, pp. 1467-1478
-
-
Gobbi, P.G.1
Zinzani, P.L.2
Broglia, C.3
-
5
-
-
34748836474
-
Is [(18)F]fluorodeoxyglucose positron emission tomography the ultimate tool for response and prognosis assessment?
-
Brepoels L, Stroobants S. Is [(18)F]fluorodeoxyglucose positron emission tomography the ultimate tool for response and prognosis assessment? Hematol Oncol Clin North Am 2007; 21:855-869.
-
(2007)
Hematol Oncol Clin North Am
, vol.21
, pp. 855-869
-
-
Brepoels, L.1
Stroobants, S.2
-
6
-
-
2642613656
-
Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglu-cose
-
Römer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglu-cose. Blood 1998; 91:4464-4471.
-
(1998)
Blood
, vol.91
, pp. 4464-4471
-
-
Römer, W.1
Hanauske, A.R.2
Ziegler, S.3
-
7
-
-
34247855900
-
PET and PET/CT for response evaluation in lymphoma: Current practice and developments
-
Brepoels L, Stroobants S, Verhoef G. PET and PET/CT for response evaluation in lymphoma: current practice and developments. Leuk Lymphoma 2007; 48:270-282.
-
(2007)
Leuk Lymphoma
, vol.48
, pp. 270-282
-
-
Brepoels, L.1
Stroobants, S.2
Verhoef, G.3
-
8
-
-
34548486030
-
-
Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25:3746-3752. This is the first clinical trial to demonstrate that FDG-PET after 2×ABVD is the only independent factor for the prediction of relapse in Hodgkin's lymphoma. This has important consequences toward the further therapeutic management in patients with Hodgkin's lymphoma, independent on the IPS.
-
Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25:3746-3752. This is the first clinical trial to demonstrate that FDG-PET after 2×ABVD is the only independent factor for the prediction of relapse in Hodgkin's lymphoma. This has important consequences toward the further therapeutic management in patients with Hodgkin's lymphoma, independent on the IPS.
-
-
-
-
9
-
-
33751576028
-
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease
-
Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006; 107:2678-2687.
-
(2006)
Cancer
, vol.107
, pp. 2678-2687
-
-
Kostakoglu, L.1
Goldsmith, S.J.2
Leonard, J.P.3
-
10
-
-
66249138001
-
Prospective evaluation on the value of FDG-PET/CT for response assessment in DLBCL after 1 week of R-CHOP (abstract 204). 10th International conference on malignant lymphoma ICML Lugano
-
4-7 June, week after treatment in DLBCL
-
Brepoels L, Stroobants S, De Wolf-Peeters C, et al. Prospective evaluation on the value of FDG-PET/CT for response assessment in DLBCL after 1 week of R-CHOP (abstract 204). 10th International conference on malignant lymphoma ICML Lugano, 4-7 June 2008. This is the first clinical trial to demonstrate the value of FDG-PET one week after treatment in DLBCL.
-
(2008)
This is the first clinical trial to demonstrate the value of FDG-PET
, vol.one
-
-
Brepoels, L.1
Stroobants, S.2
De Wolf-Peeters, C.3
-
11
-
-
66249100124
-
Early interim FDG-PET during intensified BEACOPP therapy for advanced-stage Hodgkin disease shows a lower predictive value than during ABVD (abstract 0392)
-
This is the first study indicating that accuracy of early interim FDG-PET is therapy-dependent
-
Gallamini A, Viviani S, Bonfante V, et al. Early interim FDG-PET during intensified BEACOPP therapy for advanced-stage Hodgkin disease shows a lower predictive value than during ABVD (abstract 0392). Haematologica 2007; 92 (Suppl 2):143. This is the first study indicating that accuracy of early interim FDG-PET is therapy-dependent.
-
(2007)
Haematologica
, vol.92
, Issue.SUPPL. 2
, pp. 143
-
-
Gallamini, A.1
Viviani, S.2
Bonfante, V.3
-
12
-
-
25444437438
-
Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
-
Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16:1160-1168.
-
(2005)
Ann Oncol
, vol.16
, pp. 1160-1168
-
-
Hutchings, M.1
Mikhaeel, N.G.2
Fields, P.A.3
-
13
-
-
33947512956
-
Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
-
These are the consensus guidelines for response assessment by PET in lymphoma, which are considered mandatory for end-of-treatment evaluation in Hodgkin's lymphoma
-
Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571-578. These are the consensus guidelines for response assessment by PET in lymphoma, which are considered mandatory for end-of-treatment evaluation in Hodgkin's lymphoma.
-
(2007)
J Clin Oncol
, vol.25
, pp. 571-578
-
-
Juweid, M.E.1
Stroobants, S.2
Hoekstra, O.S.3
-
14
-
-
33947496614
-
-
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-586. These are the consensus guidelines for the integration of PET and CT results for response assessment in lymphoma, which are considered mandatory for end-of-treatment evaluation in Hodgkin's lymphoma.
-
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-586. These are the consensus guidelines for the integration of PET and CT results for response assessment in lymphoma, which are considered mandatory for end-of-treatment evaluation in Hodgkin's lymphoma.
-
-
-
-
15
-
-
30144432586
-
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
-
Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107:52-59.
-
(2006)
Blood
, vol.107
, pp. 52-59
-
-
Hutchings, M.1
Loft, A.2
Hansen, M.3
-
16
-
-
35348834216
-
Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis
-
This is the most relevant prospective study in DLBCL, which shows that quantification of tumor FDG-uptake can markedly improve the accuracy of PET for prediction of patient outcome
-
Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007; 48:1626-1632. This is the most relevant prospective study in DLBCL, which shows that quantification of tumor FDG-uptake can markedly improve the accuracy of PET for prediction of patient outcome.
-
(2007)
J Nucl Med
, vol.48
, pp. 1626-1632
-
-
Lin, C.1
Itti, E.2
Haioun, C.3
-
17
-
-
0032757213
-
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations
-
Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999; 35:1773-1782.
-
(1999)
Eur J Cancer
, vol.35
, pp. 1773-1782
-
-
Young, H.1
Baum, R.2
Cremerius, U.3
-
18
-
-
33846863991
-
-
Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce thecumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109:905-909. This is the first prospective study demonstrating that risk-adapted treatment strategies by means of early PET, may allow the reduction of chemotherapy, without impairment of outcome. These findings may have important consequences toward further patient management in advanced stage Hodgkin's lymphoma.
-
Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce thecumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109:905-909. This is the first prospective study demonstrating that risk-adapted treatment strategies by means of early PET, may allow the reduction of chemotherapy, without impairment of outcome. These findings may have important consequences toward further patient management in advanced stage Hodgkin's lymphoma.
-
-
-
-
19
-
-
66249095531
-
High incidence of false-positive PET scans in patients with aggressive non-Hodgkins lymphoma treated with rituximab-containing regimens (abstract 2401)
-
December
-
Han HS, Escalon MP, Serafini A, Lossos IS. High incidence of false-positive PET scans in patients with aggressive non-Hodgkins lymphoma treated with rituximab-containing regimens (abstract 2401). 48th Meeting American Society of Haematology, 7-12 December 2006.
-
(2006)
48th Meeting American Society of Haematology, 7-12
-
-
Han, H.S.1
Escalon, M.P.2
Serafini, A.3
Lossos, I.S.4
|